For more than 2 decades, carbapenems have been considered the pharmacotherapy of last resort for managing multidrug-resistant infections caused by Enterobacteriaceae bacteria (e.g., Escherichia coli and Salmonella ). Over the past decade, however, resistance to carbapenems has emerged and appears to
No takes yet. Share an insight, caveat, or question.
Toye et al. (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: